期刊文献+

生物标志物与脓毒血症诊断及预后评估 被引量:5

Biomarkers and Diagnosis and Prognosis of Sepsis
下载PDF
导出
摘要 到目前为止,脓毒血症的发病机制以及影响疾病转归和病死率的因素均尚不明确。由于发病前没有典型的风险预测,所以早期诊断和危险分级非常困难,这些因素使脓毒血症在发病前无法得到快速、有效的治疗。生物标志物(如C反应蛋白和降钙素原)通常作为决定临床治疗方案的辅助指标,而除了这些急性期蛋白,还有很多物质对脓毒血症的诊断和预后评估具有潜在价值。 So far exact mechanisms and variables determining outcome and mortality of sepsis stay unclear. Since there is no typical risk profile, early diagnosis and risk stratification remain difficult which hin- ders the rapid and effective treatment before onset. Biomarkers like C-reactive protein and procalcitonin are routinely used as complementary tools in clinical decision-making. Beyond these acute phase proteins, a wide bunch of substances with potential diagnostic and prognostic value is under intensive investigation.
作者 王铮 安瑞华
出处 《医学综述》 2016年第15期2942-2946,共5页 Medical Recapitulate
关键词 脓毒血症 生物标志物 早期预测 Sepsis Biomarkers Early prediction
  • 引文网络
  • 相关文献

参考文献32

  • 1Vincent JL,Sakr Y,Sprung CL,et al.Sepsis in European intensive care units:results of the SOAP study[J].Crit Care Med,2006,34(2):344-353.
  • 2Gaieski DF,Edwards JM,Kallan MJ,et al.Benchmarking the incidence and mortality of severe sepsis in the United States[J].Crit Care Med,2013,41(5):1167-1174.
  • 3Li HX,Liu ZM,Zhao SJ,et al.Measuring both procalcitonin and C-reactive protein for a diagnosis of sepsis in critically ill patients[J].J Int Med Res,2014,42(4):1050-1059.
  • 4Lobo SM,Lobo FR,Bota DP,et al.C-reactive protein levels correlate with mortality and organ failure in critically ill patients[J].Chest,2003,123(6):2043-2049.
  • 5Schmit X,Vincent JL.The time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis[J].Infection,2008,36(3):213-219.
  • 6Gilbert DN.Use of plasma procalcitonin levels as an adjunct to clinical microbiology[J].J Clin Microbiol,2010,48(7):2325-2329.
  • 7Wacker C,Prkno A,Brunkhorst FM,et al.Procalcitonin as a diagnostic marker for sepsis:a systematic review and meta-analysis[J].Lancet Infect Dis,2013,13(5):426-435.
  • 8Heyland DK,Johnson AP,Reynolds SC,et al.Procalcitonin for reduced antibiotic exposure in the critical care setting:a systematic review and an economic evaluation[J].Crit Care Med,2011,39(7):1792-1799.
  • 9Lichtenstern C,Brenner T,Bardenheuer HJ,et al.Predictors of survival in sepsis:what is the best inflammatory marker to measure?[J].Curr Opin Infect Dis,2012,25(3):328-336.
  • 10Panacek EA,Marshall JC,Albertson TE,et al.Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels[J].Crit Care Med,2004,3201):2173-2182.

同被引文献46

引证文献5

二级引证文献52

;
使用帮助 返回顶部